The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials.

6533b870fe1ef96bd12cf192

RESEARCH PRODUCT

The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials.

Giuseppe Tonini Francesco Passiglia Silvia Spoto Viviana Bazan Bruno Vincenzi Francesco Pantano Antonio Galvano Michele Iuliani Daniele Santini Antonio Russo Sergio Rizzo

subject

Male medicine.medical_specialty Settore MED/06 - Oncologia Medica medicine.medical_treatment Urology Abiraterone Acetate Bone Neoplasms Abiraterone; Enzalutamide; mCRPC; rPFS; tSRE; Hematology; Oncology; Geriatrics and Gerontology Placebo Disease-Free Survival law.invention 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Randomized controlled trial law Nitriles Phenylthiohydantoin Enzalutamide Androgen Receptor Antagonists Medicine Enzalutamide Cytochrome P-450 Enzyme Inhibitors Humans 030212 general & internal medicine Progression-free survival Abiraterone tSRE Randomized Controlled Trials as Topic Chemotherapy business.industry Abiraterone acetate Hematology mCRPC medicine.disease Prostatic Neoplasms Castration-Resistant Treatment Outcome chemistry Docetaxel rPFS Oncology 030220 oncology & carcinogenesis Benzamides Disease Progression Geriatrics and Gerontology business medicine.drug

description

Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist enzalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients, using steroidal therapy or placebo as control group. Updated analyses underlined the role of these new agents on two prostate-specific endpoints as radiographic progression-free survival (rPFS) and time to first skeletal-related event (tSRE). On the basis of these reports, we made an indirect comparison between abiraterone and enzalutamide. We obtained a clinically but not significant difference favouring enzalutamide over abiraterone in terms of rPFS (HR 0.48, 95% CI 0.22â1.02). No significant difference was shown in term of tSRE (HR 0.99, 95% CI 0.83â1.17). In conclusion, abiraterone and enzalutamide have both demonstrated to significantly delay the bone progression resulting in similar improvements in bone-related endpoints in patients with mCRPC.

year	journal	country	edition	language
2017-01-01	Critical reviews in oncology/hematology

10.1016/j.critrevonc.2017.09.008 https://pubmed.ncbi.nlm.nih.gov/29110971